Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews

Latest Ratings for ARCT Date Firm Action From To Mar 2022 Wells Fargo Maintains Overweight Jan 2022 Raymond James Upgrades Underperform Market Perform Nov 2021 Barclays Maintains Underweight View More Analyst Ratings for ARCT View the Latest Analyst Ratings Importance Rank: 1 read more